Moneycontrol PRO

you are here: HomeNewsBusinessCompanies3-Point Analysis | Gland Pharma: What should investors do with stock now?

SHOW NAMES

Trending Topics

X

business

3-Point Analysis | Gland Pharma: What should investors do with stock now?

Gland Pharma's IPO subscription response was tepid compared to the recent entrants. However, it closed 21 percent higher than the issue price of Rs 1500. Let's find out what should investors do post the listing

first published: Nov 23, 2020 01:53 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347